Sanofi’s alarming $2.2B bet on dying vaccine market
The French drugmaker is acquiring a hepatitis B vaccine maker as declining U.S. vaccination rates and policy shifts reshape the industry Sanofi announced Wednesday it will acquire U.S. vaccines company Dynavax Technologies for approximately $2.2 billion, gaining access to an approved hepatitis B vaccine as the French pharmaceutical giant continues diversifying its portfolio beyond its … Read more